Pat Woolley and Paul Jaskot discuss how biotech companies can position themselves for potential acquisition by addressing intellectual property, management and diligence issues before a buyer emerges. Woolley emphasizes aligning IP protection with the company’s core technology and business strategy, including confirming ownership, assignments and freedom-to-operate considerations. Jaskot highlights the importance of experienced leadership, a well-documented history of the company and its products, and maintaining strategic options so the company can engage a buyer without first having to resolve internal issues.

(subscription required)